TSXV: ACB
VANCOUVER, March 23, 2017 /CNW/ - Aurora Cannabis Inc. (the
"Company" or "Aurora") (TSXV: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) is pleased to
announce the appointment of Dr. Barry
Waisglass as Medical Director.
Dr. Waisglass, a general practitioner, is one of Canada's most experienced physicians in the
clinical use of medical cannabis and cannabinoids. As Aurora's
Medical Director, his responsibilities include advising the Company
with respect to emerging issues and opportunities with respect to
medical cannabis, representing Aurora at Canadian and global
medical and cannabis conferences, liaising with medical
associations and colleges, participating in the development of new
products and new delivery mechanisms, as well as supporting the
Company's international market development initiatives.
Prior to his move to Aurora, Dr. Waisglass served as Medical
Director for Canadian Cannabis Clinics and CanvasRx, the country's
largest network of cannabis medical clinics and cannabis counseling
centres. In this role, he provided training to other physicians,
and treated patients affected by a wide range of health conditions,
including chronic pain, fibromyalgia, mood disorders, spasticity
caused by multiple sclerosis, chemotherapy-induced nausea, appetite
disorders and epilepsy.
Dr. Waisglass, who received his degree in medicine from the
University of Ottawa, has undergone
additional professional training in psychotherapy and psychiatric
medicine. He is currently a member of the College of Physicians and
Surgeons of Ontario, the Canadian
Medical Association, and the Ontario Medical Association.
"Barry is an important, strategic, and timely addition, as we
expand our operations in Canada
and internationally, and we are delighted that he is joining the
Aurora team," said Terry Booth, CEO.
"He is a deeply respected and widely-consulted clinical expert in
the use of cannabis as medicine, and brings invaluable new insights
and capabilities to our Company's exceptional management team."
Stock Options Grant to Directors
The Company has granted options to directors Terry Booth, CEO and Steve Dobler, President to purchase common
shares of the Company in the aggregate amount of 2,500,000 (the
"Options"). The Options will vest evenly on a quarterly basis over
three years, and are exercisable for a period of five years at
$2.27 per share.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises
Inc., is a licensed producer of medical cannabis pursuant to Health
Canada's Access to Cannabis for Medical Purposes Regulations
(ACMPR). The Company operates a 55,200 square foot,
state-of-the-art production facility in Mountain View County,
Alberta, and is currently
constructing a second 800,000 square foot production facility,
known as "Aurora Sky", at the Edmonton International Airport. The Aurora Sky
project has secured advanced technology from the most renowned
design and construction suppliers in the
Netherlands. Aurora's common shares trade on the TSX-V under
the symbol "ACB".
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth
CEO
This news release contains certain "forward-looking
statements" within the meaning of such statements under applicable
securities law. Forward-looking statements are frequently
characterized by words such as "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed" and other similar words, or
statements that certain events or conditions "may" or "will" occur.
These statements are only predictions. Various assumptions were
used in drawing the conclusions or making the projections contained
in the forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those projected in the forward-looking statements. There is no
assurance that the Proposal will be completed on the terms or
within the timeframe contemplated in this news release or at
all. The Company is under no obligation, and expressly
disclaims any intention or obligation, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as expressly required by
applicable law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Aurora Cannabis Inc.